Rick, CarolineSackley, CatherineBrady, MWoolley , R.L.Burton, ChrisPatel, S.Masterson-Algar, PatriciaNicoll, AvrilChristina, SmithJowett, SueIves, N. J.Beaton, GillianDickson, Sylvia2024-11-112024-11-112024-07-10Rick, C, Sackley, C, Brady, M, Woolley , R L, Burton, C, Patel, S, Masterson-Algar, P, Nicoll, A, Christina, S, Jowett, S, Ives, N J, Beaton, G & Dickson, S 2024, 'Lee Silverman Voice Treatment versus NHS Speech and Language Therapy versus control for dysarthria in Parkinson’s disease (PD COMM) : a UK, multicentre, pragmatic, randomised controlled trial.', BMJ, vol. 386, e078341. https://doi.org/10.1136/bmj-2023-0783410959-8146ORCID: /0000-0001-9677-4817/work/171447951https://hdl.handle.net/2164/24600Acknowledgments This study is funded by the National Institute for Health Research, Health Technology Assessment programme (HTA: 10/135/02). The views expressed are those of the authors and not necessarily those of the National Institute for Health and Care Research or the Department of Health and Social Care. We thank the members of the PD COMM DMC (Carl Counsell (chair), consultant neurologist, University of Aberdeen; Katherine Deane, Senior lecturer, University of East Anglia; and Louise Hiller, statistician, University of Warwick) and the trial steering committee (Catherine M Sackley (chief investigator), Carl E Clarke (deputy chief investigator), Pui Au, Naveed Saeed, Jane Futterer, Gillian Beaton, Marian Brady, Sue Jowett, Smitaa Patel, and Natalie Ives) for their time and support of the trial. The study authors also wish to thank Pauline Campbell for her work on reviewing the background evidence on SLT interventions for this project. We thank The Dunhill Medical Trust for funding the pilot trial, Parkinson’s UK, South Birmingham; Chris Jeffery for membership of the trial steering committee; Leslie Sharp for input to the delivery and reporting; and Tony Jefferys who reviewed the paper as a patient representative.12351284engR MedicineSupplementary DataRJournal article10.1136/bmj-2023-078341386